No quarterly revenue total was found in UNICYCIVE THERAPEUTICS, INC.'s SEC filings.
Unicycive Therapeutics, Inc. (UNCY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.6 million. As of Jun 30, 2026 it held $61.4 million in cash and investments and $671,000 in total debt.
Revenue
—
Net income
$-1.72M
+73.3% vs year-ago quarter
Operating cash flow
$-7.60M
+9.7% vs year-ago quarter
Free cash flow
$-7.61M
+9.7% vs year-ago quarter
EPS
$-0.06
+88.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
27.86M
+57.7% vs year-ago quarter
Net cash
$60.75M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UNCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1766140
- Former names
- Unicycive Therapeutics, Inc. (until Oct 29, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$10.1M | -$8.4M | -$7.2M | -$7.3M | -$7.0M |
| Net income | -$1.7M | -$12.8M | -$14.7M | -$6.0M | -$6.4M |
| Diluted EPS | -$0.06 | -$0.54 | -$0.69 | -$0.33 | -$0.52 |
| Operating cash flow | -$7.6M | -$6.2M | -$8.0M | -$6.0M | -$8.4M |
| Free cash flow | -$7.6M | -$6.2M | -$8.0M | -$6.0M | -$8.4M |
| Total assets | $72.0M | $64.4M | $49.1M | $50.6M | $30.0M |
| Total liabilities | $18.8M | $26.7M | $18.9M | $13.1M | $13.6M |
| Stockholders' equity | $53.3M | $37.7M | $30.2M | $37.5M | $16.4M |
| Cash and investments | $61.4M | $54.6M | $41.3M | $42.7M | $22.3M |
| Total debt | $671,000 | $815,000 | $117,000 | $265,000 | $409,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 19, 2026 |
All 307 Unicycive Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.